Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Renal Insufficiency: early-phase trial registry
3 of 23 indexed Renal Insufficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 3 currently recruiting · #724 of 28,707 conditions by registered trial count
Renal Insufficiency: 23 US clinical trials tracked, 3 recruiting.
Renal Insufficiency is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 6 of these trials.
Enrollment posture brief
Registry condition renal-insufficiency
OPEN 3 | RECR 13% | LATE 2 | EARLY 15 | RANK #724 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Chest Pain (13% recruiting · 23 trials)
Renal Insufficiency lists 3 open slots (13% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Renal Insufficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Renal Insufficiency is recruiting below its size-band peers.
3 of 23 indexed trials (13%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Renal Insufficiency research.
Eli Lilly and Company accounts for 6 of 23 trials (26.1%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Renal Insufficiency trials plan to enrol fewer than 100 people.
Median target enrolment is 32 among the 23 trials that report a genuine target (sentinel values excluded). 18 of those (78.3%) plan for fewer than 100 participants.
-
Renal Insufficiency research is mostly interventional.
19 interventional and 4 observational studies make up this index (82.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
VenoStent
NCT06001827
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
Eli Lilly and Company
NCT07137689
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
Eli Lilly and Company
NCT07426380
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
Eli Lilly and Company
NCT07165015
Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)
Bracco Diagnostics
NCT00773409
Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease
Bracco Diagnostics
NCT00600951
Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D
Denver Nephrologists, P.C.
NCT02492620
Glargine Dosing in Hospitalized Patients With Type 2 Diabetes and Renal Insufficiency
Loyola University
NCT00911625
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Celgene
NCT03097016
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
Eli Lilly and Company
NCT05778864
Remote Ischemic Preconditioning for Renal Protection in TAVI
Henry Ford Health System
NCT03347032
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
Novartis Pharmaceuticals
NCT03087942
A Study of Effect of Selpercatinib (LY3527723) in Participants With Normal and Impaired Renal Function
Eli Lilly and Company
NCT05469100
The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™
FAST BioMedical
NCT03095391
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
GlaxoSmithKline
NCT00501462
A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function
Janssen Research & Development
NCT01309438
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
Eli Lilly and Company
NCT05841277
Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function
Medicure
NCT01766154
Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
Ensoma
NCT04154670
A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal Insufficiency
BioCryst Pharmaceuticals
NCT01407874
Pharmacokinetics of Antiepileptics in Patients on CRRT
University of Maryland, Baltimore
NCT03632915
A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function
Cougar Biotechnology
NCT01715259
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Duke University
NCT01121770
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Renal Insufficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Renal Insufficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Renal Insufficiency page
23 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Renal Insufficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Renal Insufficiency trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Renal Insufficiency condition card totals 23 registered trials; most-linked intervention Iohexol; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.